James Gilmore

Co-Founder & CCO at SeqOnce Biosciences Inc.
Summary
James Gilmore is an accomplished marketing and sales professional with a robust background in catering to the needs of life scientists. He has excelled in various roles ranging from large companies to innovative biotechs, demonstrating expertise in acquisitions, business operations, and product launches. His key strengths lie in creativity, turning around businesses, and driving profitability.
James pursued his education in Molecular Biology, earning a Bachelor's degree and a Master's degree from San Jose State University. This academic foundation has equipped him with a deep understanding of scientific principles, enabling him to navigate the complexities of the biotechnology industry effectively.
Throughout his career, James has held several significant positions in renowned organizations. He has served as the Chief Commercial Officer at Envoke-Demos, showcasing his leadership and strategic acumen. Additionally, he co-founded SeqOnce Biosciences Inc. and BrainSpores, demonstrating his entrepreneurial spirit and innovative mindset.
James Gilmore's tenure as the Vice-President America's Marketing Leader at Life Technologies reflects his ability to drive marketing initiatives on a large scale. His role as the Marketing Lead and various directorial positions at Invitrogen underscore his diverse skill set and comprehensive understanding of the life sciences market.
With a background that includes roles such as Director of Sales Training, Director of Marketing Services, and Director of Product Development, James has honed his expertise in sales, marketing, and product management. His experience at Genometrix and Synteni, Incyte as a Founding Scientist highlights his technical proficiency and contribution to scientific advancements.
James Gilmore's professional journey is defined by a commitment to innovation, strategic leadership, and a deep understanding of the needs of life scientists. His track record of success in marketing, sales, and business development positions him as a valuable asset in the biotechnology landscape.